Semaglutide Phase 2 Trial for Opioid Use Disorder Recruiting

A Phase 2 clinical trial evaluating semaglutide, a GLP-1 receptor agonist, for opioid use disorder was listed as recruiting as of August 28, 2026. The trial, registered as NCT06548490 and titled "GLP-1R Agonist Treatment for Opioid Use Disorder," is currently in its recruitment phase according to ClinicalTrials.gov. Semaglutide is an approved compound, and this trial represents an investigation into a potential additional use. The study status indicates that researchers are actively enrolling participants, but no outcomes or results have been reported at this stage. As a Phase 2 trial, the study is designed to further assess the compound within this patient population, following any earlier phase research. No efficacy or safety findings are included in this update, only the trial's current recruiting status and phase designation. Details on trial design, eligibility, or endpoints were not provided in this event record. Readers interested in following this trial's progress can check the official registry listing for updates as recruitment continues. For more background on semaglutide, including its approved uses and general profile, readers can consult the compound overview.